Brazil to begin Phase 1 clinical trial of polylaminin for spinal cord injury

A Phase 1 clinical trial of polylaminin, a potential treatment for spinal cord injury, is set to begin, recruiting 5 volunteers to assess safety. This marks an early-stage human trial, with efficacy and broader impact still uncertain. The development is notable for advancing a novel therapeutic approach but carries low immediate market or geopolitical significance.